恒瑞医药：SHR-4610注射液获得《药物临床试验批准通知书》

Group 1 - Core viewpoint: Heng Rui Medicine has received approval for clinical trials of SHR-4610 injection from the National Medical Products Administration [1] - The revenue composition for Heng Rui Medicine in 2024 is 89.37% from pharmaceutical manufacturing and 10.63% from other businesses [1] - As of the report date, Heng Rui Medicine's market capitalization is 408.7 billion yuan [1]